- Report
- September 2025
- 250 Pages
Global
From €4045EUR$4,490USD£3,569GBP
- Report
- January 2025
- 175 Pages
Global
From €4045EUR$4,490USD£3,569GBP
- Report
- October 2025
- 199 Pages
Global
From €3193EUR$3,545USD£2,818GBP
€3548EUR$3,939USD£3,131GBP
- Report
- August 2025
- 199 Pages
Global
From €3193EUR$3,545USD£2,818GBP
€3548EUR$3,939USD£3,131GBP
- Report
- August 2025
- 199 Pages
Global
From €3193EUR$3,545USD£2,818GBP
€3548EUR$3,939USD£3,131GBP
- Report
- November 2025
- 196 Pages
Global
From €5270EUR$5,850USD£4,650GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1802EUR$2,000USD£1,590GBP
€2252EUR$2,500USD£1,987GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1081EUR$1,200USD£954GBP
€1351EUR$1,500USD£1,192GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €901EUR$1,000USD£795GBP
€1126EUR$1,250USD£994GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €901EUR$1,000USD£795GBP
€1126EUR$1,250USD£994GBP
- Report
- December 2024
- 200 Pages
Global
From €3378EUR$3,750USD£2,981GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1081EUR$1,200USD£954GBP
€1351EUR$1,500USD£1,192GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1802EUR$2,000USD£1,590GBP
€2252EUR$2,500USD£1,987GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1441EUR$1,600USD£1,272GBP
€1802EUR$2,000USD£1,590GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1081EUR$1,200USD£954GBP
€1351EUR$1,500USD£1,192GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €901EUR$1,000USD£795GBP
€1126EUR$1,250USD£994GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €901EUR$1,000USD£795GBP
€1126EUR$1,250USD£994GBP
- Report
- May 2025
- 136 Pages
Global
From €4279EUR$4,750USD£3,775GBP
- Report
- June 2025
- 147 Pages
Global
From €4414EUR$4,900USD£3,895GBP
- Report
- January 2025
- 175 Pages
Global
From €4045EUR$4,490USD£3,569GBP

Cannabidiol (CBD) is a cannabinoid found in the Cannabis sativa plant. It is a non-psychoactive compound that has been studied for its potential therapeutic effects on the central nervous system (CNS). CBD has been found to have anti-inflammatory, antioxidant, and neuroprotective properties, and has been studied for its potential to treat a variety of neurological disorders, including epilepsy, anxiety, depression, and Parkinson's disease.
CBD is increasingly being used as an alternative to traditional CNS drugs, such as benzodiazepines and opioids. It is being studied for its potential to reduce the side effects of traditional medications, as well as its potential to treat a variety of neurological conditions.
The CBD market is growing rapidly, with a variety of products available, including oils, tinctures, edibles, and topical creams. Companies in the market include Charlotte's Web, Elixinol, and Endoca. Show Less Read more